<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298946</url>
  </required_header>
  <id_info>
    <org_study_id>150021</org_study_id>
    <secondary_id>15-C-0021</secondary_id>
    <nct_id>NCT02298946</nct_id>
  </id_info>
  <brief_title>AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer</brief_title>
  <official_title>A Pilot Study of AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep
      T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in
      people with cancer. They think the drug might work even better when combined with a certain
      type of radiation therapy.

      Objective:

      - To study the safety and effectiveness of AMP-224 together with 1 or 3 days of stereotactic
      body radiation therapy (SBRT) directed to the liver.

      Eligibility:

      - People age 18 and older with metastatic colorectal cancer. Their cancer must have spread to
      the liver and not be responding to treatment.

      Design:

        -  Participants will be screened with a medical history, physical exam, and blood and urine
           tests. Their tumors will be measured with computerized tomography (CT) scans or magnetic
           resonance imaging (MRI) of the chest, stomach, and pelvis. They will have an
           electrocardiogram (ECG) heart test.

        -  Participants will have a small part of their tumor removed by needle (biopsy).

        -  Participants will have 8 study visits over about 10 weeks.

        -  At 1 visit, they will have another tumor biopsy.

        -  At 1 visit, they will get a chemotherapy drug through a vein (intravenous (IV)).

        -  At 6 visits, they will receive AMP-224 through an IV.

        -  At 1 or 3 visits, they will have SBRT. Computed tomography (CT) scans will map the
           position of their tumor. Radiation beams of different intensities at different angles
           will be directed to the tumor.

        -  At all visits, some screening procedures may be repeated.

        -  After treatment ends, participants will have 7 follow-up visits over about 5 months.
           Blood will be drawn. Some screening procedures may be repeated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Colorectal cancer remains the second leading cause of cancer death in western countries
           with a median survival of approximately 24 months despite recent advances in systemic
           treatment.

        -  Several preclinical studies have documented an increase in peripheral antitumor immunity
           following radiation, a phenomenon known as the abscopal effect. Tumor PDL1 expression
           has also been shown to be induced by radiation, which can suppress the anti-tumor immune
           response. Inhibition of programmed cell death-1 (PD-1)/programmed death ligand-1(PDL-1)
           axis has been shown to improve anti-tumor immunity by blocking the tumor-mediated
           suppression of cytotoxic T cells.

        -  AMP-224, a B7-DC Fc fusion protein, binds to PD-1, an inhibitory receptor that is
           present on the cell surface of exhausted, activated, effector, and memory T cells. AMP-
           224 has a unique mechanism of action in that it binds specifically to PD-1HI T cells
           (chronically stimulated / exhausted T cells) but not to PD-1LO cells which represent the
           normal activated T cells population

        -  The aim of the study is to evaluate whether the anti-tumor immunity of anti-PD1 therapy
           (with AMP-224) can be enhanced by radiation therapy.

      Objectives:

      - To assess safety, tolerability and feasibility of AMP-224 in combination with stereotactic
      body radiation therapy (SBRT) in patients with metastatic colorectal cancer.

      Eligibility:

        -  Histologically confirmed metastatic colorectal cancer.

        -  Patient must have progressed on or been intolerant of prior oxaliplatin- and irinotecan
           containing regimen and have metastatic lesions that are not amenable to curative
           resection.

        -  Patient must have one focus of metastatic disease in the liver that is amenable to SBRT.

        -  Patient must have at least one measurable metastatic lesion by Response Evaluation
           Criteria in Solid Tumors (RECIST) 1.1 criteria outside the radiation field.

        -  Patients must be willing to undergo mandatory pre and post treatment tumor biopsy.

      Design:

        -  This is a pilot study whereby all patients will receive SBRT to one liver lesion and
           concomitant AMP-224. A single treatment of low dose/cyclophosphamide will be
           administered in conjunction with the SBRT therapy prior to the first AMP-224 treatment.

        -  Hypofractionated radiation will be administered to a metastatic disease site at a dose
           and schedule of 8Gy for 1 or 3 days in dose levels (DL)1 or 2 respectively. The day of
           first administration of AMP-224 will be designated as Day 1. In DL1 the SBRT will be
           administered on Day 0. In DL2 the SBRT will be administered from D-2 to D0. The study
           will begin with DL1 and escalate to DL2 once all subjects enrolled at DL1 have remained
           on study for 4 weeks, which is the DLT period.

        -  AMP-224 therapy will be given as an intravenous infusion beginning on Day 1 and then
           every 14 days for a total of 6 treatments only. Optional continuation of treatment q2-
           weekly until progressive disease (PD) will be considered in responding patients.

        -  Cyclophosphamide 200 mg/m(2) intravenous will be given on Day 0, prior to the first dose
           of AMP-224.

        -  Correlative studies: Peripheral blood will be collected (pre-dose) on days 1, 29, 57 and
           93 for immune studies (including immunogenicity, circulating PD plasma samples, immune
           monitoring for phenotyping and peripheral blood mononuclear cells (PBMC) for T-cell
           activation). Tumor biopsies (formalin-fixed paraffin-embedded (FFPE) + Frozen) of an
           irradiated and non-irradiated liver lesion will be collected on day 1 and day 29, which
           will be analyzed by immunohistochemistry for tumor-infiltrating lymphocytes in addition
           to ribonucleic acid (RNA) analysis.

        -  Pharmacokinetic (PK) samples will be collected on Days 1, 15, 29, 43, 57, 71 in addition
           to up to 5 post treatment dates (if feasible).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2014</start_date>
  <completion_date type="Actual">March 7, 2017</completion_date>
  <primary_completion_date type="Actual">July 13, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 24 months and 8 days</time_frame>
    <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response in Patients With Colorectal Cancer During and Following Treatment With AMP-224 in Combination With SBRT</measure>
    <time_frame>12 months</time_frame>
    <description>Duration of overall response is measured from the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is recorded first) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is complete disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Which Specimens Were Collected for Pre and Post Pharmacokinetic (PK) AMP-224 Analyses</measure>
    <time_frame>Baseline and post infusion AMP-224 (e.g. 15 minutes after infusion ended)</time_frame>
    <description>This outcome measure only represents the number of participants with metastatic colorectal cancer who had specimens collected for pre and post pharmacokinetic (PK) AMP-224 analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Patients With Colorectal Cancer Following Treatment With AMP-224 in Combination With SBRT</measure>
    <time_frame>Baseline to end of study, which is date of death. Average time participants were followed was 10.6 months.</time_frame>
    <description>Overall survival is defined as the time from treatment start date until date of death or date last known alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Post-Treatment Biopsies</measure>
    <time_frame>Post treatment, day 29 +/- 7 days</time_frame>
    <description>Mandatory post treatment biopsies of the tumor were attempted on all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival in Patients With Colorectal Cancer</measure>
    <time_frame>Baseline to disease progression, an average of 2.6 months.</time_frame>
    <description>Progression free survival is defined as the time interval from start of treatment to documented evidence of disease progression. Disease progression was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Restaging was done every 8 weeks for an average of 2.6 months.</time_frame>
    <description>Objective response will be evaluated according to the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and is defined as Complete Response + Partial Response. Briefly, complete response (CR) is defined as the disappearance of all target lesions, and Partial Response is defined as &quot;at least&quot; 30% decrease in the sum of the diameters of the target lesions from baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of AMP-224 as Measured by Human Anti-Murine Antibodies (HAMA) and Human Anti-Chimeric Antibodies (HACA) Concentrations</measure>
    <time_frame>Baseline, D1, D29, and D57 (pre-infusion), D79, D85 and 90 days post last dose (D169)</time_frame>
    <description>Blood samples were collected to measure HAMA and HACA concentrations using the ELISA method in all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life of AMP-224</measure>
    <time_frame>10 days</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration of the drug to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of the Curve (AUC) of AMP-224</measure>
    <time_frame>Pre and post-infusion with all the AMP infusion and Day 1 at 8, 15, 29, 43, 57, and 71 hours.</time_frame>
    <description>The AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. The lower limit of quantification (LLOQ) is the smallest concentration of the drug that can be reliably measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of AMP-224</measure>
    <time_frame>12.7 hours following intravenous (IV) infusion.</time_frame>
    <description>Time maximum drug absorption is reached in the blood following administration of AMP-224.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>DL1 - CTX, SBRTx1 day, &amp; AMP-224</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0. Stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days for a total of 6 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DL2 - CTX, SBRTx3 days, and AMP-224</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, and 0. AMP-224 10mg/kg on day 1 then q14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMP-224</intervention_name>
    <description>10mg/kg on day 1 then every 14 days for a total of 6 doses.</description>
    <arm_group_label>DL1 - CTX, SBRTx1 day, &amp; AMP-224</arm_group_label>
    <arm_group_label>DL2 - CTX, SBRTx3 days, and AMP-224</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy(SBRT)</intervention_name>
    <description>Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days</description>
    <arm_group_label>DL1 - CTX, SBRTx1 day, &amp; AMP-224</arm_group_label>
    <arm_group_label>DL2 - CTX, SBRTx3 days, and AMP-224</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>200mg/m(2) IV on day 0.</description>
    <arm_group_label>DL1 - CTX, SBRTx1 day, &amp; AMP-224</arm_group_label>
    <arm_group_label>DL2 - CTX, SBRTx3 days, and AMP-224</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -Inclusion Criteria

          1. Patients must have histopathological confirmation of Colorectal Carcinoma (CRC) by the
             Laboratory of Pathology of the National Cancer Institute (NCI) prior to entering this
             study.

          2. Patients must have progressed on or been intolerant of prior oxaliplatin and
             irinotecan containing chemotherapeutic regimen and have disease that is not amenable
             to potentially curative resection. Patients who have a known KRAS wild type tumor must
             have progressed or been intolerant to cetuximab or panitumumab-based chemotherapy.

          3. Patients must have one focus of metastatic disease in the liver that is amenable to
             stereotactic body radiation therapy (SBRT) in the opinion of radiation oncology.

          4. All patients enrolled will be required to have measurable disease by Response
             Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria outside the radiation field.

          5. Study patients must have disease that is amenable to pre and post treatment biopsy and
             be willing to undergo this.

          6. Age greater than or equal 18 years

          7. Life expectancy of greater than 3 months

          8. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          9. Patients must have acceptable organ and marrow function as defined below:

               -  leukocytes less than or equal to 3,000/mcL

               -  absolute neutrophil count less than or equal 1,500/mcL

               -  platelets less than or equal 100,000/mcL

               -  total bilirubin greater than or equal 1.5X institution upper limit of normal

               -  Patients are eligible with alanine aminotransferase (ALT) or aspartate
                  aminotransferase (AST) measuring up to 5 x ULN given the presence of liver
                  metastasis.

               -  creatinine greater than 1.5X institution upper limit of normal

             Or

             -creatinine clearance less than or equal 45 mL/min/1.73 m(2), as calculated below, for
             patients with creatinine levels above institutional normal

         10. Patients must have recovered from any acute toxicity related to prior therapy,
             including surgery. Toxicity should be less than or equal to grade 1 or returned to
             baseline.

         11. Patients must not have other invasive malignancies within the past 3 years (with the
             exception of non-melanoma skin cancers, localized prostate cancer, carcinoma in situ
             of the cervix and non-invasive bladder cancer that has had successful curative
             treatment).

         12. Patient must be able to understand and willing to sign a written informed consent
             document.

        Exclusion Criteria

          1. Prior immune checkpoint inhibition with anti-programmed cell death-1 (PD1)/programmed
             death ligand-1(PD-L1) or anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) therapy or
             other specific T cell targeting agents.

          2. Patients who have had chemotherapy (or so-called targeted systemic therapy), large
             field radiotherapy, or major surgery must wait 4 weeks after completing treatment
             prior to entering the study.

          3. Patients with known brain metastases will be excluded from this clinical trial because
             of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events.

          4. Uncontrolled intercurrent illness including, but not limited to, hypertension
             (systolic blood pressure (BP) greater than 160, diastolic BP greater than 100),
             ongoing or active systemic infection, symptomatic congestive heart failure, unstable
             angina pectoris, cardiac arrhythmia, uncontrolled diabetes or psychiatric
             illness/social situations that would limit compliance with study requirements.

          5. Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy
             are excluded from this study due to the possibility of pharmacokinetic interactions
             between antiretroviral medications and the investigational agent.

          6. History of chronic autoimmune disease (e.g., systemic lupus erythematosus or Wegener's
             granulomatosis, Addison's disease, multiple sclerosis, Graves disease, Hashimoto's
             thyroiditis, hypophysitis, etc.) with symptomatic disease within the 3 years before
             randomization. Note: Active vitiligo or a history of vitiligo will not be a basis for
             exclusion. In addition, a past history of certain autoimmunity eg rheumatoid arthritis
             or thyroiditis may be allowed per principal investigator (PI) discretion provided it
             has been quiescent for a minimum of three years.

          7. Active or history of inflammatory bowel disease (colitis, Crohn's), irritable bowel
             disease, celiac disease, or other serious, chronic, gastrointestinal conditions
             associated with diarrhea.

          8. Dementia or significantly altered mental status that would prohibit the understanding
             or rendering of Information and Consent and compliance with the requirements of the
             protocol.

          9. Currently receiving immunosuppressive doses of steroids or other immunosuppressive
             medications (inhaled and topical steroids are permitted)

         10. History of sarcoidosis syndrome

         11. History of hypersensitivity reaction to human or mouse antibody products.

         12. Pregnancy and breast feeding are exclusion factors. The effects of AMP-224 on the
             developing human fetus are unknown. Enrolled patients must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry, the duration of study participation and 3 months after the end of the
             treatment. Should a woman become pregnant or suspect she is pregnant while she or her
             partner is participating in this study, she should inform her treating physician
             immediately.

         13. Patients with unhealed surgical wounds for more than 30 days.

         14. Patients with known sensitivity or allergy to any components of AMP-224.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim F Greten, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2015-C-0021.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011 Mar;8(3):151-60. doi: 10.1038/nrclinonc.2010.223. Review.</citation>
    <PMID>21364688</PMID>
  </reference>
  <reference>
    <citation>Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007 Sep;13(9):1050-9. Epub 2007 Aug 19.</citation>
    <PMID>17704786</PMID>
  </reference>
  <reference>
    <citation>Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007 Jan;13(1):54-61. Epub 2006 Dec 24.</citation>
    <PMID>17187072</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <results_first_submitted>October 4, 2018</results_first_submitted>
  <results_first_submitted_qc>February 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 22, 2019</results_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Tim Greten, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anti-PD1 Therapy</keyword>
  <keyword>Anti-Tumor Immunity</keyword>
  <keyword>Liver Metastatic</keyword>
  <keyword>B7-DC Fc Fusion Protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02298946/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02298946/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
          <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
        </group>
        <group group_id="P2">
          <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
          <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unevaluable</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
          <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
        </group>
        <group group_id="B2">
          <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
          <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="17.2"/>
                    <measurement group_id="B2" value="57.3" spread="14.5"/>
                    <measurement group_id="B3" value="58.8" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Not meeting the definition for Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexican,Puerto Rican,Cuban,Central or So. Amer/Oth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Count of Participants with Pre-Treatment Biopsies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</title>
        <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 24 months and 8 days</time_frame>
        <population>One patient (on dose level 1) after signing consent while waiting for radiation dosing, developed a spinal cord compression that needed emergent care at the local hospital. This patient was not treated. One patient (on dose level 1) after signing consent, developed a bowel obstruction prior to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
          <group group_id="O2">
            <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
            <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</title>
          <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <population>One patient (on dose level 1) after signing consent while waiting for radiation dosing, developed a spinal cord compression that needed emergent care at the local hospital. This patient was not treated. One patient (on dose level 1) after signing consent, developed a bowel obstruction prior to treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response in Patients With Colorectal Cancer During and Following Treatment With AMP-224 in Combination With SBRT</title>
        <description>Duration of overall response is measured from the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is recorded first) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is complete disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.</description>
        <time_frame>12 months</time_frame>
        <population>Zero participants were analyzed because no participants experienced a CR or PR.</population>
        <group_list>
          <group group_id="O1">
            <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
          <group group_id="O2">
            <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
            <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response in Patients With Colorectal Cancer During and Following Treatment With AMP-224 in Combination With SBRT</title>
          <description>Duration of overall response is measured from the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is recorded first) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is complete disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.</description>
          <population>Zero participants were analyzed because no participants experienced a CR or PR.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Which Specimens Were Collected for Pre and Post Pharmacokinetic (PK) AMP-224 Analyses</title>
        <description>This outcome measure only represents the number of participants with metastatic colorectal cancer who had specimens collected for pre and post pharmacokinetic (PK) AMP-224 analyses.</description>
        <time_frame>Baseline and post infusion AMP-224 (e.g. 15 minutes after infusion ended)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
          <group group_id="O2">
            <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
            <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Which Specimens Were Collected for Pre and Post Pharmacokinetic (PK) AMP-224 Analyses</title>
          <description>This outcome measure only represents the number of participants with metastatic colorectal cancer who had specimens collected for pre and post pharmacokinetic (PK) AMP-224 analyses.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre AMP-224</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post AMP-224</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Patients With Colorectal Cancer Following Treatment With AMP-224 in Combination With SBRT</title>
        <description>Overall survival is defined as the time from treatment start date until date of death or date last known alive.</description>
        <time_frame>Baseline to end of study, which is date of death. Average time participants were followed was 10.6 months.</time_frame>
        <population>Patients were follow up post completion of the treatment medications for survival until date of their death. 2 patients were not evaluable since they did not receive treatment. 1 patient was lost to follow up after 3 cycles of treatment due to brain metastasis and treatment in another state.</population>
        <group_list>
          <group group_id="O1">
            <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
          <group group_id="O2">
            <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
            <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Patients With Colorectal Cancer Following Treatment With AMP-224 in Combination With SBRT</title>
          <description>Overall survival is defined as the time from treatment start date until date of death or date last known alive.</description>
          <population>Patients were follow up post completion of the treatment medications for survival until date of their death. 2 patients were not evaluable since they did not receive treatment. 1 patient was lost to follow up after 3 cycles of treatment due to brain metastasis and treatment in another state.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="1.2" upper_limit="8.9"/>
                    <measurement group_id="O2" value="9.0" lower_limit="1.5" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Post-Treatment Biopsies</title>
        <description>Mandatory post treatment biopsies of the tumor were attempted on all patients.</description>
        <time_frame>Post treatment, day 29 +/- 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
          <group group_id="O2">
            <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
            <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Post-Treatment Biopsies</title>
          <description>Mandatory post treatment biopsies of the tumor were attempted on all patients.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival in Patients With Colorectal Cancer</title>
        <description>Progression free survival is defined as the time interval from start of treatment to documented evidence of disease progression. Disease progression was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).</description>
        <time_frame>Baseline to disease progression, an average of 2.6 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
          <group group_id="O2">
            <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
            <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival in Patients With Colorectal Cancer</title>
          <description>Progression free survival is defined as the time interval from start of treatment to documented evidence of disease progression. Disease progression was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.9" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.3" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <description>Objective response will be evaluated according to the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and is defined as Complete Response + Partial Response. Briefly, complete response (CR) is defined as the disappearance of all target lesions, and Partial Response is defined as &quot;at least&quot; 30% decrease in the sum of the diameters of the target lesions from baseline measurement.</description>
        <time_frame>Restaging was done every 8 weeks for an average of 2.6 months.</time_frame>
        <population>All patients had restaging evaluations completed as per protocol. Response criteria in solid tumors(RECIST) were completed on every trial participate. No partial or complete responses were found in any patients.</population>
        <group_list>
          <group group_id="O1">
            <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
          <group group_id="O2">
            <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
            <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>Objective response will be evaluated according to the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and is defined as Complete Response + Partial Response. Briefly, complete response (CR) is defined as the disappearance of all target lesions, and Partial Response is defined as &quot;at least&quot; 30% decrease in the sum of the diameters of the target lesions from baseline measurement.</description>
          <population>All patients had restaging evaluations completed as per protocol. Response criteria in solid tumors(RECIST) were completed on every trial participate. No partial or complete responses were found in any patients.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of AMP-224 as Measured by Human Anti-Murine Antibodies (HAMA) and Human Anti-Chimeric Antibodies (HACA) Concentrations</title>
        <description>Blood samples were collected to measure HAMA and HACA concentrations using the ELISA method in all patients.</description>
        <time_frame>Baseline, D1, D29, and D57 (pre-infusion), D79, D85 and 90 days post last dose (D169)</time_frame>
        <population>Data was collected and not analyzed because the outside laboratory declined to run specimens with a negative clinical trial.</population>
        <group_list>
          <group group_id="O1">
            <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
          <group group_id="O2">
            <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
            <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of AMP-224 as Measured by Human Anti-Murine Antibodies (HAMA) and Human Anti-Chimeric Antibodies (HACA) Concentrations</title>
          <description>Blood samples were collected to measure HAMA and HACA concentrations using the ELISA method in all patients.</description>
          <population>Data was collected and not analyzed because the outside laboratory declined to run specimens with a negative clinical trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life of AMP-224</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration of the drug to decrease by one half.</description>
        <time_frame>10 days</time_frame>
        <population>Data was collected and not analyzed because the outside laboratory declined to run specimens with a negative clinical trial.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0 Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life of AMP-224</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration of the drug to decrease by one half.</description>
          <population>Data was collected and not analyzed because the outside laboratory declined to run specimens with a negative clinical trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area of the Curve (AUC) of AMP-224</title>
        <description>The AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. The lower limit of quantification (LLOQ) is the smallest concentration of the drug that can be reliably measured.</description>
        <time_frame>Pre and post-infusion with all the AMP infusion and Day 1 at 8, 15, 29, 43, 57, and 71 hours.</time_frame>
        <population>Data was collected and not analyzed because the outside laboratory declined to run specimens with a negative clinical trial.</population>
        <group_list>
          <group group_id="O1">
            <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
          <group group_id="O2">
            <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
            <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Area of the Curve (AUC) of AMP-224</title>
          <description>The AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. The lower limit of quantification (LLOQ) is the smallest concentration of the drug that can be reliably measured.</description>
          <population>Data was collected and not analyzed because the outside laboratory declined to run specimens with a negative clinical trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax) of AMP-224</title>
        <description>Time maximum drug absorption is reached in the blood following administration of AMP-224.</description>
        <time_frame>12.7 hours following intravenous (IV) infusion.</time_frame>
        <population>Data was collected and not analyzed because the outside laboratory declined to run specimens with a negative clinical trial.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0 Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
Cyclophosphamide: 200mg/m(2) IV on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax) of AMP-224</title>
          <description>Time maximum drug absorption is reached in the blood following administration of AMP-224.</description>
          <population>Data was collected and not analyzed because the outside laboratory declined to run specimens with a negative clinical trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 24 months and 8 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DL1 - CTX, SBRTx1 Day, &amp; AMP-224</title>
          <description>Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0, stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses. Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days Cyclophosphamide: 200mg/m(2) IV on day 0</description>
        </group>
        <group group_id="E2">
          <title>DL2 - CTX, SBRTx3 Days, and AMP-224</title>
          <description>Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days AMP-224: 10mg/kg on day 1 then every 14 days for a total of 6 doses. Stereotactic Body Radiation Therapy(SBRT): Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days Cyclophosphamide: 200mg/m(2) IV on day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <description>malignant neoplasm</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="16" subjects_affected="8" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="14" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="19" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="30" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <description>urinary discomfort</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <description>outside CT scan, suggests pt might have pneumonia or increased lung lesion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Papulopustular rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <description>diaphoresis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tim F. Greten</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-451-4723</phone>
      <email>gretentf@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

